Skip to main content
S&P 5007,614.77-0.55%DOW52,450.44-0.23%NASDAQ26,108.73-0.85%BTC$78,127.00+1.69%ETH$2,499.15+0.84%GOLD$4,319.10-2.04%OIL$103.96+3.91%
Smart Investors Daily
CO

NASDAQ · COYA

Coya Therapeutics, Inc.

Healthcare · Biotechnology

$4.38

Down-$0.14 (-3.10%)

Updated Sep 14, 2026, 1:22 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
104.01M
P/E ratio
-0.02
Dividend yield
0.00%
52-week range
$3.71 – $6.21
Volume
139.34K
Avg. volume
191.64K

Price performance

COYA price history

1M range · 19 trading sessions · Daily adjusted prices

COYA closed at $4.38 after 19 trading sessions, down 6.21% for the selected period.

Last close
$4.38
Period change
-6.21%
Period low
$4.38
Period high
$5.04
Daily close
View OHLC price history
COYA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$4.59$4.66$4.37$4.38139.34K
Sep 10, 2026$4.61$4.62$4.455$4.5293.46K
Sep 9, 2026$4.55$4.695$4.53$4.6177.82K
Sep 8, 2026$4.82$4.82$4.595$4.6198.35K
Sep 4, 2026$4.54$4.77$4.52$4.7675.76K
Sep 3, 2026$4.50$4.58$4.36$4.55100.32K
Sep 2, 2026$4.53$4.6485$4.39$4.4261.9K
Sep 1, 2026$4.52$4.6295$4.48$4.51101.25K
Aug 31, 2026$4.58$4.6982$4.51$4.5647.43K
Aug 28, 2026$4.82$4.82$4.55$4.59153.11K
Aug 27, 2026$5.14$5.14$4.76$4.8677.62K
Aug 26, 2026$5.02$5.0299$4.83$4.8754.4K
Aug 25, 2026$4.99$5.22$4.98$5.04145.19K
Aug 24, 2026$4.89$5.26$4.71$4.96147.07K
Aug 21, 2026$4.90$4.95$4.805$4.8770.95K
Aug 20, 2026$5.00$5.00$4.73$4.8659.52K
Aug 19, 2026$4.96$5.10$4.95$4.97118.87K
Aug 18, 2026$4.65$4.93$4.65$4.92106.65K
Aug 17, 2026$4.81$4.81$4.63$4.6767.28K

Latest COYA news

The latest Smart Investors Daily articles mentioning COYA.

Stock researchCompany · Overview

COYA research

Overview

Company profile and research snapshot.

Company profile

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$17.00
Implied upside
—
Analysts
13
COYA recent ratings
DateFirmRatingTarget
Aug 24, 2026Roth CapitalBuy—
Aug 12, 2026Chardan CapitalBuy—
Jun 12, 2026Chardan CapitalBuy—
Jun 5, 2026Roth CapitalBuy—
Apr 10, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

HOUSTON, September 08, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, "The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease," which highlights the expanding therapeutic app

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By